Nine Diagnostics Joins American Cancer Society’s BrightEdge Entrepreneurs Program

Nine Diagnostics Joins American Cancer Society’s BrightEdge Entrepreneurs Program

Nine Diagnostics, a leader in AI-enabled nanosensor technology, has been selected to participate in the American Cancer Society’s BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate the most promising oncology-focused startups. This selection marks another significant milestone for Nine Diagnostics as it continues to drive innovation in cancer treatment selection, dosing, optimization, and monitoring.